Focusing On Stocks With Great Upside In Past 5 days: $KCAC $TCON $ATNX

The Market Signal was created as a platform to help investors, if you own (NYSE:KCAC), (NASDAQ:TCON) or (NASDAQ:ATNX) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

(Click link above or copy, paste and hit enter in your browser for your report)


(Click link above or copy, paste and hit enter in your browser for your report)

KENSINGTON CAP (NYSE:KCAC) has beat its last week's performance by a margin of 90.25%.

Kensington Capital Acquisition Corp. (NYSE: KCAC) and QuantumScape Corporation have come together in a merger, in which case they will be operating using the ticker symbol "QS".

The business combination has QuantumScape obtain proceeds totalling to about $700. Million.

The Qatar Investment Authority (QIA) and by the Volkswagen Group led the Series F financing. This initiative had QuantumScape achieve about $1 billionin funding commitments and cash. QuantumScape and Volkswagen have been looking forward to that time when the VW's vehicles could use the solid-state batteries. The two come together to form a joint venture that will facilitate the industrial-level production of the products. The combined company's value stands at about $3.3 billion as clearly stated in the Proforma

TRACON Pharmaceuticals focuses on ENVASARC pivotal study

(Click link above or copy, paste and hit enter in your browser for your report)

TRACON Pharmaceuticals Inc. (NASDAQ:TCON) performance has climbed to hit the one for last week by a margin of 65.50%.

The company's private placement of pre-funded warrants and common stock has helped it accumulate about $5.0 million. That was possible after it managed to lure several institutional health care focused funds in a definitive securities purchase agreement.

TRACON won't shift from its plan to sell common stock shares totalling to about 3.0 million. This company channels the $5.0 million towards the purchase of $5.0 million shares. The exercise price for each share will be at about $0.01 for the pre-funded warrants. This deal is set to expire in about seven years from the day of issuance.

The ENVASARC pivotal study of envafolimab is the company's priority at the moment. It seeks to utilize the net proceeds obtained from the private placement to fund the study. The U.S. Food and Drug Administration cleared the ENVASARC on August 14, 2020.

Athenex receives application Priority Review from FDA

(Click link above or copy, paste and hit enter in your browser for your report)

Athenex Inc. (NASDAQ:ATNX) performance this time around scaled above last week's by a margin of 40.74%.

Athenex is impressed by the U.S. Food and Drug Administration (FDA) move to give its New Drug Application (NDA) the application Priority Review. Its objective is to succeed in the treatment metastatic breast cancer. The target action date set by the US body in line with the application is February 28, 2021.The body has also dismissed the idea about the holding of an advisory committee meeting in line with discussions surrounding the application.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.


comtex tracking


Is there a problem with this press release? Contact the source provider Comtex at